7
Views
20
CrossRef citations to date
0
Altmetric
Original Articles

Effect of Intra-arterial versus Intravenous Cisplatin in Addition to Systemic Adriamycin and High-Dose Methotrexate on Histologic Tumor Response of Osteosarcoma of the Extremities

, , , , , , , , , , & show all
Pages 189-195 | Published online: 15 Jul 2016

References

  • Bacci G, Picei P, Ruggieri P et al. Primary chemotherapy and delayed surgery (neoadjuvent chemotherapy) for osteosarcoma of the extremities. The Rizzoli experience in 127 patients treated preoperatively with methotrexate i.v. (high vs moderate dose) and cisplatinum i.a. Cancer 1990; 65: 2539–2553.
  • Bacci G, Picei P, Pignatti G et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Clin Orthoped 1991; 270: 87–98.
  • Benjamin RS, Chawla SP, Carrasco C et al. Arterial infusion in the treatment of osteosarcoma. In: Ryan JR and Baker O : Recent concepts in sarcoma treatment. Kluver Academic Publisher, 1988: 269–274.
  • Goorin AM, Perez-Atayde A, Gebhardt M et al.Weekly high-dose methotrexate and doxorubicin for osteosarcoma. The Dana-Farber Cancer Institute/ the Children’s Hospital Study III. J Clin Oncol 1987; 5: 1178–1184.
  • Kalifa C, Mlika N, Dubusset J et al. The experience of T10 protocol in the pediatric department of the Goustave Roussy Institute. In: Ryan JR, Baker O: Recent concepts in sarcoma treatment. Kluwer Academic Publisher 1988: 301–305.
  • Rosen G. Preoperative chemotherapy (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten years experience. Orthopaedics 1985; 8: 659–664.
  • Winkler K, Beron G, Kotz R et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984; 2: 617–624.
  • Winkler K, Beron G, Delling G et al. Neoadjuvant chemotherapy of osteosarcoma. Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329–337.
  • Jaffe N, Raymond K, Ayala A et al. Intra-arterial cisdiammine-dichloroplatinum II in pediatric oseosarcoma: relationship of the effect on primary tumor to survival. In: Ryan JR, Baker O: Recent concepts in sarcoma treatment. Kluver Academic Publisher 1988: 275–282.
  • Rosen G, Marcove R, Caparros B et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163–2177.
  • Rosen G. The current management of malignant bone tumors: where do we go from here? Med J Austral 1988; 148: 373–377.
  • Winkler K, Bielack S, Delling et al. Effect of intraarterial versus intravenous cisplatinum in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer 1990; 66: 1703–1710.
  • Picei G, Bacci G, Campanacci M et al. Histological evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer 1985; 56: 1515–1521.
  • Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthoped 1980; 153: 106–120.
  • Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight G. Adjuvant chemotherapy foe osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5: 21–26.
  • Rosen G, Caparros B, Huvos AG et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to the preoperative chemotherapy. Cancer 1982; 49: 1221–1230.
  • Stewart DJ, Benjamin RS, Zimmermann RS et al. Clinical pharmacology of intraarterial Cis DDP (II). Cancer Res 1983; 43: 917–920.
  • Mangues R, Giraldez J, Bilbao JI et al. Clinical and experimental pharmacokinetics of intraarterial cisplatin (CDDP). Advantage over intravenous. Proc ECCO 1987; 4: 75.
  • Withrow S, Powers B, Straw RC et al. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthoped 1991; 270: 159–168.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.